Human papillomavirus vaccination in the resourced and resource-constrained world

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 25, Issue 5, 2011, Pages 597-603

  Woo, Yin Ling ^a   Omar, Siti Z ^a  

^a UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

Author keywords

Cervical cancer; Developed world; Human papillomavirus (HPV) vaccination; Poverty; Resource constrained world

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CANCER CONTROL; CANCER IMMUNIZATION; CANCER PREVENTION; CULTURAL FACTOR; HEALTH PRACTITIONER; HEALTH PROGRAM; HUMAN; PAPILLOMAVIRUS INFECTION; POVERTY; PRIORITY JOURNAL; RELIGION; UTERINE CERVIX CANCER; WART VIRUS; DEVELOPED COUNTRY; DEVELOPING COUNTRY; FEMALE; HEALTH; HEALTH CARE DELIVERY; REVIEW; UTERINE CERVIX TUMOR; VACCINATION;

DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION; WORLD HEALTH;

EID: 84858223604     PISSN: 15216934     EISSN: 15321932     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2011.05.004     Document Type: Review

References (44)

1. Parkin D. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118: 3030-3044.
2. Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19. (Pubitemid 29406813)
3. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human papillomavirus and related cancers in World. Summary Report 2010, www.who.int/hpvcentre [Last accessed 14.05.11].
4. Silvia de S, Wim GVQ, Laia A et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048-1056.
5. Chaturvedi AK. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health 2010; 46(4 Suppl): S20-S26.
6. Mork J, Moller B, Dahl T et al. Time trends in pharyngeal cancer incidence in Norway 1981-2005: a subsite analysis based on a reabstraction and recoding of registered cases. Cancer Causes Control 2010; 21: 1397-1405.
7. Robinson D, Coupland V & Moller H. An analysis of temporal and generational trends in the incidence of anal and other HPV-related cancers in Southeast England. Br J Cancer 2009; 100: 527-531.
8. Stanley M. HPV: immune response to infection and vaccination. Infect Agent Cancer 2010; 5: 19.
9. Frazer IH. Measuring serum antibody to human papillomavirus following infection or vaccination. Gynecol Oncol 2010; 118(Suppl. 1): S8-S11.
10. Stanley M. Human papillomavirus vaccines versus cervical cancer screening. Clin Oncol (R Coll Radiol) 2008; 20: 388-394.
11. Munoz N, Kjaer SK, Sigurdsson K et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010; 102: 325-339.
12. Paavonen J, Naud P, Salmeron J et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301-314.
13. Cuzick J. Long-term cervical cancer prevention strategies across the globe. Gynecol Oncol 2010; 117(Suppl. 1): S11-S44.
14. Donovan B, Franklin N, Guy R et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis (in press).
15. Romanowski B. Long term protection against cervical infection with human papillomavirus: review of currently available vaccines. Hum Vaccine 2011: 7 (Epub ahead of print).
16. David MP, Van Herck K, Hardt K et al. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol 2009; 115: S1-S6.
17. Fraser C, Tomassini JE, Xi L et al. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine 2007; 25: 4324-4333. (Pubitemid 46635934)
18. Wenzel JJ & Jilg W. Loss of antibodies, but not of protection. Lancet Infect Dis 2010; 10: 738-739.
19. Garland S. Can cervical cancer be eradicated by prophylactic HPV vaccination? Challenges to vaccine implementation. Indian J Med Res 2009; 130: 311-321.
20. Dorleans F, Giambi C, Dematte L et al. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. Euro Surveill 2010; 15: 19730.
21. Kliewer EV, Demers AA & Elliott L. Twenty-year trends in the incidence and prevalence of diagnosed anogenital warts in Canada. Sex Transm Dis 2009; 36: 380-386.
22. Richards L. Epidemiology: human papillomavirus: a powerful predictor of survival in patients with oropharyngeal cancer. Nat Rev Clin Oncol 2010; 7: 481.
23. Kane MA. Global implementation of human papillomavirus (HPV) vaccine: lessons from hepatitis B vaccine. Gynecol Oncol 2010; 117(Suppl. 1): S32-S35.
24. Hakim A & Dinh T. Worldwide impact of the human papillomavirus vaccine. Curr Treat Options Oncol 2009; 10: 44-53.
25. Krishnan S, Dunbar MS, Minnis AM et al. Poverty, gender inequities, and women's risk of human immunodeficiency virus/ AIDS. Ann N Y Acad Sci 2008; 1136: 101-110. (Pubitemid 351862166)
26. Lester FBN & Fathalla MMF. Global Women's Health in 2010: facing the challenges. J Womens Health (Larchmt) 2010; 19: 2081-2089.
27. Agosti JM & Goldie SJ. Introducing HPV vaccine in developing countries: key challenges and issues. N Engl J Med 2007; 356: 1908-1910. (Pubitemid 46740300)
28. Goldie SJ, O'Shea M, Diaz M et al. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications. Reprod Health Matters 2008; 16: 86-96.
29. Perry A. New meningitis vaccine: a model for the developing world. Time Magazine 2010, http://www.time.com/time/health/article/0,8599,2034886,00.html [accessed 14.05.11].
30. Fleurence RL, Dixon JM, Milanova TF et al. Review of the economic and quality-of-life burden of cervical human papillomavirus disease. Am J Obstet Gynecol 2007; 196: 206-212. (Pubitemid 46341227)
31. Brown RE, Breugelmans JG & Theodoratou D. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin 2006; 22: 663-670.
32. Bonevski B, Sanson-Fisher R, Girgis A et al. Womens experiences of having a colposcopic examination: self-reported satisfaction with care, perceived needs and consequences. J Obstet Gynaecol 1998; 18: 462-470. (Pubitemid 28461540)
33. Karasz A, McKee MD & Roybal K. Women's experiences of abnormal cervical cytology: illness representations, care processes, and outcomes. Ann Fam Med 2003; 1: 196-202.
34. Charo RA. Politics, parents, and prophylaxis: mandating HPV vaccination in the United States. N Engl J Med 2007; 356: 1905-1908. (Pubitemid 46740299)
35. Zimet G, Weiss T, Rosenthal S et al. Reasons for non-vaccination against HPV and future vaccination intentions among 19- 26 year-old women. BMC Womens Health 2010; 10: 27.
36. Pruitt SL & Schootman M. Geographic disparity, area poverty, and human papillomavirus vaccination. Am J Prev Med 2010; 38: 525-533.
37. Mortensen G. Drivers and barriers to acceptance of human-papillomavirus vaccination among young women: a qualitative and quantitative study. BMC Public Health 2010; 10: 68.
38. Ogilvie G, Anderson M, Marra F et al. A population-based evaluation of a publicly funded, school-based HPV vaccine program in British Columbia, Canada: parental factors associated with HPV vaccine receipt. PLoS Med 2010; 7: e1000270.
39. Laurent-Ledru V, Thomson A & Monsonego J. Civil society: a critical new advocate for vaccination in Europe. Vaccine 2010.
40. Torvinen S, Nieminen P, Lehtinen M et al. Cost effectiveness of prophylactic HPV 16/18 vaccination in Finland: results from a modelling exercise. J Med Econ 2010; 13: 284-294.
41. Olsen J & Jepsen MR. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Int J Technol Assess Health Care 2010; 26: 183-191.
42. Garnett GP, Kim JJ, French K et al. Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006; 24(Suppl. 3): S178-S186. (Pubitemid 44293028)
43. Food and Drug Administration. Gardasil approved to prevent anal cancer 2010, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm237941.htm [last accessed 14.05.11].
44. World Health Organization. WHO position on HPV vaccines. Vaccine 2009; 27: 7236-7237.